One possible explanation for the competitive advantage that malignant cells in patients with acute myelogenous leukemia (AML) appear to have over normal hematopoietic elements is that leukemic progenitors proliferate more rapidly than their normal progenitor cell counterparts. To test this hypothesis, an overnight 
Introduction
In spite of the abnormalities in hematopoietic cell differentiation which are obvious in the blast cells from patients with acute myelogenous leukemia (AML) the malignant clone appears to be maintained by a hierarchy of progenitor cell types very similar to that seen in normal hematopoiesis. [1] [2] [3] [4] [5] These malignant progenitors include cells which form colonies of blasts in semisolid media when provided with a source of hematopoietic growth factors (AML colony-forming cells or AML-CFC) and more primitive and rare cells which initiate long-term malignant hematopoiesis when co-cultured with a supportive fibroblast feeder layer and cytokines (AML longterm culture-initiating cells or AML LTC-IC). 6, 7 These AML LTC-IC, like their normal LTC-IC counterparts, give rise to daughter CFC after 5 or more weeks in culture and are at least 10-fold less frequent in the malignant cell population than the directly clonogenic AML-CFC. 7 The apparent competitive advantage that malignant hematopoiesis exhibits over normal blood cell production in AML patients cannot be explained by the proliferation of leukemic blasts, most of which have very limited proliferative potential. However, it has been demonstrated that most AML-CFC are in active cell cycle while normal CFC and LTC-IC, particularly in steady-state peripheral blood, are largely quiescent. [8] [9] [10] It appears likely that the more active proliferation of leukemic progenitors contributes to the dominance of the leukemic clone in vivo.
The molecular basis for this continuous leukemic progenitor proliferation has not been completely elucidated but, at least in some cases, may be related to autocrine or paracrine growth factor production by AML blasts. 11, 12 The cytokines produced by leukemic cells permit a degree of factorindependent AML-CFC growth in vitro and appear to facilitate engraftment and proliferation of AML cells in vivo in immunodeficient mice. 5 Thus, it seems likely that escape from normal growth controls through this and perhaps other mechanisms is a feature of malignant progenitors throughout the leukemic cell hierarchy. The current study was undertaken to characterize the proliferative status of AML LTC-IC, the most primitive AML progenitors that can be detected in vitro, and to compare the cycling status of AML LTC-IC to the more 'differentiated' AML-CFC and, where possible, normal progenitors from the same patient sample.
For these studies an overnight 3 H-thymidine ( 3 H-Tdr) suicide assay was used. In this technique the period of exposure to 3 H-Tdr is extended from the usual 20 min to 16-24 h to allow all cells in a homogeneously cycling population to pass through S-phase during the incubation period. The results of previous studies with normal CFC and leukemic cell lines are consistent with the prediction that the maximum cell kill observed would increase from the 50% typically seen with the 20 min technique to 100% with the more prolonged 3 HTdr incubation. 9 The variability inherent in the LTC-IC assay makes the increased differential cell kill obtained with 16-24 h 3 H-thymidine incubation necessary to allow cycling and noncycling populations of LTC-IC to be reliably distinguished. Using this assay Ponchio et al 9 have shown that normal LTC-IC from steady-state peripheral blood are quiescent while the cycling status of those in the bone marrow is more heterogeneous. In both cases, however, 72 h exposure to appropriate growth factors was sufficient to trigger quiescent LTC-IC into active cell cycle. Using this same technique, we now demonstrate that a large proportion leukemic LTC-IC as well as CFC in the peripheral blood of patients with newly diagnosed AML are in active cell cycle. However, a significant proportion of quiescent progenitors could also be recognized in most AML samples.
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Materials and methods
Cell preparation
Peripheral blood (PB) samples were obtained from newly diagnosed AML patients with the approval of the Clinical Screening Committee for Research Involving Human Subjects of the University of British Columbia and after obtaining informed consent. Light density mononuclear cells were isolated by Ficoll-Hypaque (Pharmacia, Uppsala, Sweden) density gradient separation and cryopreserved in DMEM with 50% fetal calf serum (FCS) and 10% dimethylsulfoxide (DMSO). All leukemic samples were evaluated at diagnosis for blast morphology, histochemical staining characteristics and cell surface phenotype following which they were classified by the clinical diagnostic laboratory into French-American-British subtypes. 13 Standard metaphase cytogenetic analysis was performed on diagnostic bone marrow specimens. Eight of the nine patient samples chosen had cytogenetic markers that were easily detectable by FISH. The clinical characteristics of the nine patients studied are listed in Table 1 .
Overnight ( 3 H-Tdr) suicide assay
The method has been described in detail previously. 9 Briefly, fresh or thawed cryopreserved AML cells were resuspended at 2 × 10 6 cells/ml in serum-free media containing 20% serum substitute BIT (StemCell Technologies, Vancouver, Canada), 2 mmol/l L-glutamine and 2 × 10 −5 mol/l ␤-mercaptoethanol. In most experiments 100 ng/ml human Steel factor (SF) (Terry Fox Laboratory, Vancouver, Canada), 20 ng/ml interleukin-3 (IL-3) (Novartis, Basel, Switzerland) and 20 ng/ml granulocyte colony-stimulating factor (G-CSF) (Amgen, Thousand Oaks, CA, USA) were added to the overnight culture. However, in some experiments the growth factors were varied as indicated in Table 2 . Equal volumes of this cell suspension were plated into 100-mm petri dishes (Corning, NY, USA) in the presence or absence of 20 Ci/ml of high specific activity 3 H-Tdr (25 Ci/mmol; Amersham, Oakville, Canada) and incubated at 37°C in an atmosphere of 5% CO 2 in air. After 16-24 h 400 g/ml cold thymidine (Sigma-Aldrich Canada, Oakville, Ontario, Canada) was added. Cells were then washed with 40 g/ml cold thymidine in Iscove's medium with 2% FCS and resuspended in Myelocult (StemCell Technologies) medium prior to plating in AML colony-forming cell (AML CFC) and long-term culture-initiating cell (AML LTC-IC) assays. 
Colony assays and long-term cultures
Freshly isolated and thawed cryopreserved cells were assayed immediately or after overnight culture for AML CFC. Cells were plated at 0.2 to 2 × 10 5 cells/ml in methylcellulose-based medium (0.92% methylcellulose, 30% FCS, 2 mmol/l L-glutamine, 10 −4 mol/l ␤-mercaptoethanol, 1% bovine serum albumin in ␣-medium; StemCell) supplemented with the following growth factors: 3 U/ml erythropoietin (StemCell), 20 ng/ml each of IL-3, IL-6 (Terry Fox Laboratory), G-CSF and granulocyte-macrophage colony-stimulating factor (GM-CSF) (Novartis, Basel, Switzerland), 50 ng/ml each of SF and Flt-3 ligand (FL) (Immunex, Seattle, WA, USA). Colonies were scored using an inverted microscope after 10-14 days culture at 37°C. 7 LTC of AML cells were performed as previously described. 7 Briefly, 4-5 × 10 6 light density AML cells in 2.7 ml Myelocult media (StemCell) with 10 −6 mol/l solucortef (Sigma-Aldrich Canada) and 100 ng/ml SF were seeded on to a confluent layer of irradiated (80 Gy) mouse embryonic fibroblasts (Sl/Sl) which had been engineered to produce human IL-3 (Sl/Sl-J-IL-3) 14 in a 35-mm tissue culture dish. These fibroblast feeder layers secrete 16 ng/ml human IL-3 into their growth medium as determined by the ability of this medium to stimulate 3 HTdr incorporation into Mo7e cells. 15, 16 LTC were incubated at 37°C in 5% CO 2 with weekly half medium change. SF was added to the cultures twice weekly to maintain a final concentration of 100 ng/ml. After 5 weeks, both the adherent and nonadherent cells were harvested (the former by trypsinization), pooled and plated into methylcellulose assay as described above.
Fluorescence in situ hybridization (FISH)
Individual colonies were picked from methylcellulose assays into hypotonic KCl solution (0.075 mol/l) and fixed in 3:1 methanol:acetic acid on multiwell glass slides (Celline Assoc., New Field, NJ, USA). In some cases colony cells were synchronized in metaphase as previously described. 17 This was particularly necessary to allow identification of the t(8;20) in colonies from patient 2 with the chromosome 8 FISH painting probe. The plasmid library DNAs for chromosome 8 (a gift from Dr D Pinkel, University of California at San Francisco, CA, USA) and plasmid DNAs containing the 8 centromerespecific DNA (D8Z2; ATCC, Rockville, MD, USA) were labeled with digoxigenin (DIG, Digoxigenin-11-dUTP; Boehringer-Mannheim, Laval, Canada) using a nick translation kit (Life Technologies, Burlington, Canada). A bacteria artificial chromosome clone (b-IL9 or b-393) for chromosome 5q31 (gifts from Dr L Nagarajan, University of Texas, MD Anderson Cancer Center, Houston, TX, USA) and DNA containing 9q34(c-abl) sequences (a gift from Dr E Henske, Harvard Medical School, MA, USA) were first amplified by inter-Alu polymerase chain reaction (PCR) using primers and conditions described previously 18 and then labeled with DIG. The 11q23(MLL) probe labeled with DIG was purchased from Oncor (Gaithersburg, MD, USA).
The slides containing individual colonies were prepared and hybridized overnight with the denatured DNA probes using the method described previously. 7 The post-hybridization washing steps for the different probes are as follows: chromosome 8 painting probe: at 45°C, twice with 55% formamide in 4 × SSC (NaCl, 0.6 M, Na 3 C 6 H 5 O 7 .2H 2 O, 0.06 M, pH 7) for 15 min, 2 × SSC for 15 min, 0.5 × SSC for 5 min and 0.1 × SSC for 5 min. 8 centromere probe: at 45°C, twice with 50% formamide in 4 × SSC for 15 min, twice in 55% formamide in 4 × SSC for 15 min, 2 × SSC for 15 min, and twice in 0.1 × SSC for 15 min. 9q34 probe: at 43°C, three times in 50% formamide in 4 × SSC for 5 min and three times in 2 × SSC for 5 min. MLL (11q23) Oncor probe and 5q31 PCR probe: at 45°C, twice with 50% formamide in 4 × SSC for 15 min and 2 × SSC for 15 min.
At least 10 colonies were individually plucked from methylcellulose cultures of each experimental group of LTC and direct AML-CFC assays. Colonies were scored as normal or abnormal when more than five cells from the colony had a clear FISH signal and when more than 80% of the cells in an individual colony gave the same signal.
Calculations and statistical analysis
Equal numbers of AML cells were placed in overnight culture with or without For calculation of the proportion of cytogenetically normal or abnormal progenitors which were cycling, the number of CFC in direct methylcellulose assay or assays from LTC of cells which had or had not been exposed to 3 H-Tdr was multiplied by the % normal or abnormal colonies detected by FISH. These values were then used to calculate the % kill of the two populations using the formula above.
The statistical significance of differences between groups was calculated by 2 analysis or Student's t-test as indicated.
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Results
Maintenance of AML progenitor cell numbers in short-term culture
In initial experiments the ability of serum-free culture conditions to maintain AML CFC and LTC-IC numbers at input levels overnight was tested. AML PB cells were first cultured in serum-free medium with SF, G-CSF and IL-3 since this growth factor combination had been formerly shown to maintain normal CFC and LTC-IC without a significant change in their numbers for up to 24 h. 9 Table 2 shows that on average the numbers of AML CFC and LTC-IC did not change significantly from input values over 16-24 h under these culture conditions in the absence of 3 H-Tdr. The mean % recoveries of CFC and LTC-IC among nine AML samples were 78 ± 33 and 126 ± 53, respectively. Subsequently, the effects of five different growth factor combinations and serum-free medium alone were compared on progenitor numbers from three of the AML samples (from patients 2, 3 and 9). All of these conditions appeared to be equivalent for short-term maintenance of AML progenitors (Table 2 ). With two patient samples the relative proportions of cytogenetically abnormal and normal CFC and LTC-IC detected by FISH were not significantly different in cultures containing SF, G-CSF and IL-3 as compared to cultures with serum-free medium alone (proportion of cytogenetically abnormal progenitors detected after culture without vs with growth factors 100% and 86% vs 100% and 68% for AML-CFC and 22% and 0% vs 14% and 0% for AML LTC-IC for patients 2 and 3, respectively). In subsequent experiments to assess progenitor cycling status the originally tested conditions using SF, G-CSF and IL-3 were used to allow direct comparison with the previously reported experiments with normal peripheral blood. 9 
Cycling status of fresh and cryopreserved AML-CFC
To determine the cycling status of leukemic progenitors, light density mononuclear cells from the peripheral blood of newly diagnosed AML patients were incubated in the presence or absence of high specific activity 3 H-Tdr for 16-24 h. In initial experiments the effect of cryopreservation on the cycling activity of AML-CFC was evaluated since we had a large bank of cryopreserved AML samples available for analysis. As shown in Table 3 , AML CFC from these initial three samples were largely in active cell cycle when freshly isolated from AML patient blood as expected from the previous work of other investigators. 8 Furthermore, neither their numbers nor their cycling status was significantly altered by prior cryopreservation (P Ͼ 0.05 by paired Student's t-test).
In subsequent experiments using cryopreserved specimens, AML-CFC from a total of nine patient samples were studied as shown in Table 4 . The mean ± s.d. % kill for all nine samples was 64 ± 27. Six of these nine samples showed more than 50% progenitor cell kill following 3 H-Tdr exposure while in three samples (from patients 1, 4 and 6) the majority of AML-CFC were quiescent. In two of these latter three, all the quiescent CFC could be shown to carry the cytogenetic abnormality expected in the malignant clone. Interestingly, incubation of cells from patient 4 with 3 H-Tdr allowed some cytogenetically normal CFC to be detected which were not seen in the absence of 3 H-Tdr and there was a significant (P Ͻ 0.05, 2 ) increase in the proportion of cytogenetically normal colonies for patient 3 in the presence of 3 H-Tdr. (3) a The percentages of input progenitor numbers after 16-24 h in culture were calculated by dividing the number of progenitors detected after culture by the progenitor number detected when cells were assayed immediately after thawing. Results are expressed as mean % input ± s.d. (numbers of samples tested). b Abbreviations and final concentrations of the growth factors: S, SF, 100 ng/ml; F, FL, 100 ng/ml; 3, IL-3, 20 ng/ml; 6, interleukin 6, 20 ng/ml; G, G-CSF, 20 ng/ml; T, thrombopoietin, 1000 U/ml. When only the relative numbers of cytogenetically abnormal CFC in the suicide assays with or without 3 H-Tdr were considered, a higher % kill of malignant progenitors was calculated for these two samples and that from patient 7. However, on average the mean ± s.d. % kill of cytogenetically abnormal AML-CFC was 68 ± 26, ie not significantly different from the value calculated for % kill of total CFC. 
Cycling status of AML LTC-IC
After overnight culture with or without exposure to 3 H-Tdr AML cells from the same nine patients were plated in LTC-IC assays. As shown in Table 5 the mean % kill ± s.d. for the total LTC-IC populations detected in these assays was 82 ± 16 indicating a predominantly cycling progenitor population. In fact, in no case was the % kill detected less than 50%. As expected from our previous studies of AML samples in LTC, 7, 19 in six patient samples a significant number of cytogenetically normal LTC-IC could be detected. The mean % kill by 3 H-Tdr of these seemingly normal progenitors (74% ± 20) was comparable to that of the cytogenetically abnormal AML LTC-IC (85% ± 13). However, in two cases (cells from patients 1 and 7) exposure to 3 H-Tdr increased the proportion of cytogenetically normal LTC-IC significantly (P Ͻ 0.02 by 2 ). To test whether or not the presence of growth factors in the overnight incubation with 3 H-Tdr would affect the cycling status of AML CFC or LTC-IC, cells from two patient samples were incubated for 16 h in serum-free medium either with or without the 'standard' growth factor cocktail (SF + G-CSF + IL-3). As shown in Table 6 , there was no reduction in the % kill of either progenitor cell type when the growth factors were removed. Without GF, serum-free medium without growth factor additions. b S + 3 + G, serum-free medium supplemented with SF 100 ng/ml, + IL-3 20 ng/ml, + G-CSF 20 ng/ml.
Discussion
We have previously demonstrated that co-culture of leukemic blasts from patients with AML for at least 5 weeks with supportive fibroblast feeder layers and cytokines allows identification and quantitation of a rare, primitive malignant progenitor analogous to normal long-term culture-initiating cells. We have termed these cells AML LTC-IC. 7 Most of these AML LTC-IC are found within the CD34 +
CD38
− fraction of leukemic cells and thus have a cell surface phenotype similar to both normal LTC-IC and primitive AML progenitors which initiate growth in immunodeficient mice. 3, 4, 20 It is thus likely that at least some of the primitive malignant cells detected in the LTC system can maintain leukemic hematopoiesis in human patients. To improve our understanding of leukemic stem cell biology and potentially aid in the rational design of new therapeutic regimens we sought to identify differences in the growth characteristics of AML LTC-IC and their normal cell counterparts.
One possibility that might explain the growth advantage that malignant hematopoiesis has over normal blood cell production in vivo is an increased proliferative fraction among the leukemic progenitor cell compartment. In fact, it has been previously demonstrated that AML progenitors which form colonies in growth factor-supplemented methylcellulose are a more actively cycling population than normal CFC. 8 Our goal
Leukemia in the current study was to extend these observations to the more primitive leukemic progenitor cell compartment represented by AML LTC-IC. Test cells were exposed to 3 H-Tdr overnight to maximize our ability to discriminate predominantly cycling from quiescent progenitor populations in the LTC-IC assay. Since the duration of one mitotic cycle in eukaryotic cells is 16-24 h, exposure of cells to 3 H-Tdr for this time period allows all cells in different phases of active cell cycle to pass through S phase where the labeled nucleoside can be incorporated into newly synthesized DNA and the cell subsequently killed. 9 In previous studies where this method was validated for use with normal human hematopoietic progenitors appropriate controls showed that there was no effective reutilization of 3 H-Tdr with the overnight incubation. The concentration of 3 H-Tdr used and the period of exposure was sufficient to obtain a maximum kill value of 100% as compared to the more traditional assay using a 20 min 3 H-Tdr exposure where the average maximum cell kill is 50%. 9 In the current study we demonstrated that neither the number of AML LTC-IC nor their cycling status changed over the 16-24 h incubation period whether or not growth factors were present in the culture medium. Similar findings have been reported for normal CFC and LTC-IC in steady-state peripheral blood. 9 Furthermore, prior cryopreservation also did not change the cycling status of AML CFC, allowing this assay to be performed on frozen samples from our stored bank of leukemic cells.
In previous studies, using the same 3 H-Tdr technique employed in these experiments, both directly clonogenic cells and LTC-IC from normal steady-state peripheral blood were found to be quiescent (mean % kill of both progenitor cell types Ͻ20%).
9 Interestingly, LTC-IC from normal steady-state bone marrow or mobilized peripheral blood have a larger proliferative fraction. 9, 21 Thus, many AML progenitors in the blood of untreated patients contrast with normal blood progenitors by being in active cell cycle and thus appear more similar to normal marrow progenitors in this regard.
We have previously recognized a large number of cytogenetically normal LTC-IC in the blood from many AML patients. 7 It is apparent from both clinical and experimental observations that multiple genetic events are usually required to produce AML and that the 'preleukemic' clone may precede or coexist with frank leukemia and re-emerge after Leukemia apparently successful treatment. [22] [23] [24] [25] However, it is also wellestablished that normal polyclonal hematopoiesis persists in patients with AML and is usually re-established in chemotherapy-induced remission. 26, 27 Using X-chromosome inactivation-based assays of clonality, we are currently attempting to determine whether the cytogenetically normal progenitors we detect in assays of AML cells are part of the leukemic clone or represent truly normal, polyclonal hematopoiesis. 28 In these current experiments it is interesting that the majority of cytogenetically normal LTC-IC detected in AML patient blood were actively proliferating, in contrast to the highly quiescent state of LTC-IC found in normal steady-state blood. It is possible that factors prevalent in the leukemic process in vivo, such as autocrine growth factor production by the leukemic blasts, stimulate the proliferation (or mobilization from the marrow) of normal LTC-IC. 11, 12 In spite of the apparent similarity in the proportion of normal and abnormal LTC-IC in active cell cycle detected in the current experiments, leukemic hematopoiesis was clearly dominant in vivo in these newly diagnosed AML patients. Thus, it is likely that additional differences between the leukemic clone and normal hematopoietic cells, such as a lower frequency of apoptotic cell death 29 or shorter cell cycle time 30 are necessary to permit AML progenitors to prevail over their normal counterparts in vivo.
Although a substantial proportion of AML CFC and LTC-IC are in active cell cycle in newly diagnosed patients, it is interesting that the % kill obtained in the overnight 3 H-Tdr suicide assay was significantly less than 100% in many patient samples, ie six of nine and five of nine samples tested in the AML-CFC and AML LTC-IC assays, respectively (Tables 4 and  5 ). Some of the progenitors which survived exposure to 3 HTdr carried the cytogenetic marker characteristic of the malignant clone in all the AML-CFC assays and four of the five AML LTC-IC assays. These data demonstrate a reservoir of quiescent leukemic progenitors which may be resistant to standard chemotherapeutic agents. They further suggest that efforts to trigger active cycling in this population may enhance the efficacy of such regimens. Experiments are in progress to determine if growth factors which stimulate the short-term proliferation of AML blasts and support AML CFC growth in methylcellulose assay can stimulate the entry of quiescent AML CFC and LTC-IC into active cycle. Other investigators have suggested that at least some of the AML progenitors which initiate cobblestone areas in LTC and growth in severe combined immunodeficient mice may be quiescent, further supporting the relevance of such studies. 31 The current data contrast with those obtained using the same 3 H-Tdr suicide assay on peripheral blood progenitors from patients with chronic myelogenous leukemia (CML) where Ͼ99% kill of both leukemic CFC and LTC-IC was obtained. 32 The variability in the proliferative status of AML progenitors from different patient samples as compared to the consistent and homogeneously cycling status of analogous cells from patients with CML no doubt reflects the greater heterogeneity in the recognized cellular and molecular changes associated with the former as compared to the latter diagnosis.
